{"id":"NCT03002038","sponsor":"Isfahan University of Medical Sciences","briefTitle":"Comparison of Clinical Effects of Azathioprine and Rituximab NMO-SD Patients","officialTitle":"Comparison of Annual Relapse Rate, Expanded Disability Status Scale, and Side Effects Between Azathioprine and Rituximab in Patients With Neuromyelitis Optica Spectrum Disorders","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2015-09","primaryCompletion":"2016-11","completion":"2016-12","firstPosted":"2016-12-23","resultsPosted":"2020-09-30","lastUpdate":"2020-09-30"},"enrollment":86,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Neuromyelitis Optica Spectrum Disorder"],"interventions":[{"type":"DRUG","name":"Azathioprine","otherNames":["Azathioprine Mehrdaru®"]},{"type":"DRUG","name":"Rituximab","otherNames":["RediTux®"]}],"arms":[{"label":"Azathioprine","type":"EXPERIMENTAL"},{"label":"Rituximab","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to compare annual relapse rate, expanded disability status scale, and side effects of azathioprine and rituximab in patients with neuromyelitis optica spectrum disorder during a one year follow up through a randomized clinical trial.","primaryOutcome":{"measure":"Annual Relapse Rate","timeFrame":"one year","effectByArm":[{"arm":"Azathioprine","deltaMin":1,"sd":0.38},{"arm":"Rituximab","deltaMin":1.3,"sd":0.68}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":16},"locations":{"siteCount":1,"countries":["Iran"]},"refs":{"pmids":["24118482","22617743","21813788","24272588","23897062","27261687","28831548"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":46},"commonTop":["Mild/moderate allergic reactions","Gastrointestinal intolerance"]}}